...
首页> 外文期刊>Journal of pharmaceutical sciences. >PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug.
【24h】

PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug.

机译:PLGA纳米颗粒用于口服递送疏水性药物:使用雌二醇作为模型药物,有机溶剂对纳米颗粒形成和体外和体内释放行为的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of present investigation was to screen different solvents for optimizing nanoparticle preparation in terms of particle size, entrapment efficiency, and finally, release behavior using a model drug estradiol. Nanoparticles were prepared following emulsion-diffusion-evaporation method using didodecyldimethyl ammonium bromide (DMAB) or polyvinyl alcohol (PVA) as stabilizers. Ethyl acetate (EA), acetone (ACE), chloroform (CHL), and dichloromethane (DCM) were used as organic solvents either individually or in combinations. DMAB when used as surfactant led to smaller particle size as compared to PVA irrespective of the solvents and combinations used, but on the other hand, PVA produced particles with higher entrapment when combinations of solvents used. DCM in combination with EA resulted in highest entrapment with both the stabilizers. All the formulations exhibited similar in vitro release profile (Zero order) irrespective of stabilizer (DMAB or PVA) used, however, the average release per day was higher in case of DCM formulations due to greater entrapment. In situ uptake studies suggest that smaller the particle size better is the uptake. The bioavailability from nanoparticles was assessed in male Sprague Dawley (SD) rats at a dose of 1 mg drug/rat. EA/DMAB (size 116.0 +/- 2.6 nm) and DCM:EA 70:30/DMAB (size 253.0 +/- 5.5 nm) showed the release for 9 and 5 days, respectively, whereas EA/PVA (size 279.3 +/- 2.5 nm) released the drug over the periods of 3 days suggesting that particle size has significant role in determining the fate of nanoparticles in vivo. Histopathological examination revealed absence of any inflammatory response with the formulations under the studied period.
机译:本研究的目的是使用模型药物雌二醇筛选不同的溶剂,以优化粒径,包封效率以及最终的释放行为,从而优化纳米颗粒的制备。通过乳化-扩散-蒸发法,使用十二烷基二甲基溴化铵(DMAB)或聚乙烯醇(PVA)作为稳定剂制备纳米颗粒。乙酸乙酯(EA),丙酮(ACE),氯仿(CHL)和二氯甲烷(DCM)分别用作有机溶剂或组合使用。 DMAB用作表面活性剂时,与PVA相比,粒度更小,而与使用的溶剂和组合无关,但另一方面,当使用溶剂组合时,PVA产生的颗粒具有更高的截留率。 DCM与EA结合使用时,两种稳定剂的包封率最高。不论使用哪种稳定剂(DMAB或PVA),所有制剂均表现出相似的体外释放曲线(零级),但是,由于更大的截留,因此DCM制剂的每日平均释放量更高。原位吸收研究表明,较小的颗粒尺寸更好。在雄性Sprague Dawley(SD)大鼠中以1 mg药物/大鼠的剂量评估了纳米颗粒的生物利用度。 EA / DMAB(尺寸116.0 +/- 2.6纳米)和DCM:EA 70:30 / DMAB(尺寸253.0 +/- 5.5纳米)分别释放了9天和5天,而EA / PVA(尺寸279.3 + / -2.5 nm)在3天的时间内释放了药物,表明粒径在决定体内纳米颗粒的命运方面具有重要作用。组织病理学检查显示在研究期间该制剂不存在任何炎症反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号